H.C. Wainwright sets USD 10.00 target for Ocugen stock

Published on 10/20/2026 at 18:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Ocugen booked USD 1.49 million revenue in second-quarter 2026. Ocugen stock costs EUR 0.74 on October 20, 2026, while Nasdaq quotes USD 0.83.

Analyst view and reporting date

H.C. Wainwright reiterated a Buy rating and set a USD 10.00 target on October 1, 2026.
Ocugen reported USD 1.49 million in second-quarter 2026 revenue and a USD 24.88 million GAAP net loss.
Ocugen stock was trading at EUR 0.74 at Lang & Schwarz on October 20, 2026 at 6:38 p.m. CEST.
Stockanalysis lists November 4, 2026 as the estimated next earnings date.

OCGN, US67577C1053, Illustration mit AI erstellt.

H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating and set a USD 10.00 price target for Ocugen on October 1, 2026, according to Markets Insider. Ocugen stock was trading at EUR 0.74 at Lang & Schwarz on October 20, 2026 at 6:38 p.m. CEST.

Analyst target stays far above the quote

The USD 10.00 target follows H.C. Wainwright's reiterated Buy view. The same report said Canaccord Genuity maintained a Buy rating with an USD 11.00 target in a report released on September 29, 2026, according to Markets Insider. These targets are stated in USD, while the headline price is the euro quotation.

Second-quarter figures show the funding pressure

Ocugen generated USD 1.49 million of revenue in the second quarter of 2026, compared with USD 1.37 million in the second quarter of 2025. GAAP net loss reached USD 24.88 million, versus USD 14.74 million a year earlier, according to Markets Insider. Finance statements show diluted GAAP earnings per share of minus USD 0.07 for the quarter ended June 30, 2026, compared with minus USD 0.06 in the first quarter of 2026.

Nasdaq range and upcoming date

On the Nasdaq, Ocugen was quoted at USD 0.83 on October 20, 2026 at 12:45 p.m. EDT, with a market capitalization of USD 282.7 million and a 52-week range of USD 0.78 to USD 2.73. The quote was up USD 0.05, or 5.91 percent, from the Nasdaq prior close of USD 0.79. The Nasdaq listing and company identity are also stated by Stockanalysis.

Stockanalysis lists November 4, 2026 as the estimated next earnings date. Ocugen's pipeline centers on gene therapies for blindness diseases, including OCU400 and OCU410, while its latest reported cash balance was USD 100.1 million at June 30, 2026.

What the next report could clarify

The November reporting date gives investors a defined checkpoint for revenue, spending and cash usage. The latest quarterly operating cash flow was negative USD 12.2 million, while second-quarter revenue of USD 1.49 million covered only a fraction of the USD 24.88 million GAAP net loss. The figures leave the USD 10.00 and USD 11.00 analyst targets dependent on clinical and commercial progress rather than current earnings.

Ocugen stock stays below its yearly high

At Lang & Schwarz, Ocugen stock was trading at EUR 0.74 on October 20, 2026 at 6:38 p.m. CEST. The primary Nasdaq quote was USD 0.83 on October 20, 2026 at 12:45 p.m. EDT. The further course of trading is shown by the continuously updated real-time quote of Ocugen stock.